New strategy aims to boost surgery success in pancreatic cancer
NCT ID NCT04539808
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The study also tests adding the drug losartan to the chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (mFOLFIRINOX, gemcitabine/nab-paclitaxel, and losartan)
What this could lead to
If successful, this approach could improve the chances of completely removing pancreatic cancer during surgery, potentially extending survival.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to all patients. Chemotherapy side effects can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States